Doses studied
Ipamorelin dosage, as recorded in the research — not a protocol
What was administered, to which species, by which route, in published studies. No human dosing guidance.
The short version
This page describes ipamorelin dosage the way the studies report it — what researchers gave to animals or volunteers, and how the body cleared it — and nothing more. It is not a how-to and it carries no recommendation for any person. The numbers that are solid are the pharmacokinetic ones: in humans, ipamorelin has a terminal half-life of about 2 hours, and the growth-hormone pulse it triggers peaks roughly 40 minutes after a dose [2]. The animal doses span a wide range depending on what was being measured — bone growth, body weight, or chemotherapy-related weight loss [4][5]. The popular CJC-1295 plus ipamorelin "stack" protocols circulating online have no peer-reviewed human dosing basis; they are community conventions, described here as anecdotal, not as instructions.
Doses studied, by model
In the human pharmacokinetic study, single intravenous doses of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg were infused over 15 minutes [2]. In the only human Phase 2 efficacy trial, the dose was 0.03 mg/kg intravenously twice daily for up to seven days [3]. In rodent body-composition work, the bone-growth study used 18, 90, and 450 μg/day subcutaneously, divided three times daily over 15 days [4], and a bone-mineral study used 0.5 mg/kg/day by continuous subcutaneous osmotic minipump for 12 weeks. The 2024 ferret cachexia study used 1 to 3 mg/kg intraperitoneally [5]. These figures are reported here as study parameters in named species — they are not converted to, and must not be read as, a human dose.
Routes studied
Ipamorelin has been administered intravenously (the route in human pharmacokinetic and clinical work, and in much rodent efficacy testing), subcutaneously (the dominant route in rodent bone and body-composition studies, and in community use), intranasally (rodent pharmacokinetics, with about 20% bioavailability [11]), and intraperitoneally (rodent and ferret efficacy studies [5]). Oral administration applies only to engineered ipamorelin-derived analogs — roughly 10% bioavailable in dogs for one lead compound [13] — because ipamorelin itself is not orally bioavailable. Route matters because it shapes how much intact peptide reaches the circulation and how the growth-hormone pulse is timed.
How long does ipamorelin stay in your system
In healthy human volunteers, ipamorelin showed a terminal half-life of approximately 2 hours, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response is a single discrete pulse peaking about 40 minutes (0.67 h) after dosing, not a sustained elevation [2]. As a half-life of roughly 2 hours, the parent peptide is largely cleared within a day; in rats, plasma clearance is about 5-fold lower than GHRP-6, and 60 to 80% of a dose is recovered intact in bile and urine [11]. These are measured pharmacokinetic values, not a guide to timing any personal use.
How much cjc-1295 ipamorelin should i take
There is no peer-reviewed human dose for the CJC-1295 plus ipamorelin combination, so no responsible figure can be given. The combination has never been tested in a controlled human trial for any outcome, and the single combination-specific result in the literature is a murine muscle-loss study, not a human dosing study [16]. The protocols shared in peptide communities are anecdotal conventions without controlled-trial support and are not reproduced here as guidance. What the literature does provide is single-agent ipamorelin pharmacokinetics — a ~2-hour half-life and a ~40-minute growth-hormone pulse [2] — which is mechanism, not a prescription.
How to reconstitute cjc-1295 ipamorelin 5mg
Ipamorelin is supplied as a lyophilized (freeze-dried) powder, as either the free base or the acetate salt, and is reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw cycles, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature, not a clinical preparation instruction and not a directive for any human use. The specific volume used to reconstitute a given vial is a laboratory handling choice, not a dose this site endorses.